Onset of amyopathic dermatomyositis following <scp>mRNA</scp>‐based <scp>SARS‐CoV</scp>‐2 vaccination

Kreuter, Alexander; Lausch, Sara; Burmann, Sven‐Niklas; Paschos, Alexandros; Michalowitz, Alena‐Lioba

doi:10.1111/jdv.18211

Cited by 13 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Out of 24 patients with dermatomyositis (DM), all had skin rashes, with many having Gottron's papules [11,56,58,59,62,65,66,103,112,132,147,149,152,162,190]. One-fifth of patients (6) had no muscle weakness [11,65,103,112,147]. A total of eight patients had interstitial lung disease (ILD) [59,65,103,112,152,190].…”

Section: Idiopathic Inflammatory Myositismentioning

confidence: 99%

See 1 more Smart Citation

New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review

Nune,

Durkowski,

Pillay

et al. 2023

Vaccines

View full text Add to dashboard Cite

A comprehensive, up-to-date systematic review (SR) of the new-onset rheumatic immune-mediated inflammatory diseases (R-IMIDs) following COVID-19 vaccinations is lacking. Therefore, we investigated the demographics, management, and prognosis of new R-IMIDs in adults following SARS-CoV-2 vaccinations. A systematic literature search of Medline, Embase, Google Scholar, LitCovid, and Cochrane was conducted. We included any English-language study that reported new-onset R-IMID in adults following the post-COVID-19 vaccination. A total of 271 cases were reported from 39 countries between January 2021 and May 2023. The mean age of patients was 56 (range 18–90), and most were females (170, 62.5%). Most (153, 56.5%) received the Pfizer BioNTech COVID-19 vaccine. Nearly 50% of patients developed R-IMID after the second dose of the vaccine. Vasculitis was the most prevalent clinical presentation (86, 31.7%), followed by connective tissue disease (66, 24.3%). The mean duration between the vaccine’s ‘trigger’ dose and R-IMID was 11 days. Most (220, 81.2%) received corticosteroids; however, 42% (115) received DMARDs such as methotrexate, cyclophosphamide, tocilizumab, anakinra, IV immunoglobulins, plasma exchange, or rituximab. Complete remission was achieved in 75 patients (27.7%), and 137 (50.6%) improved following the treatment. Two patients died due to myositis. This SR highlights that SARS-CoV-2 vaccines may trigger R-IMID; however, further epidemiology studies are required.

show abstract

Section: Idiopathic Inflammatory Myositismentioning

confidence: 99%

“…Both patients had positive anti-transcription intermediary factor 1 (TIF-1) antibodies. The other three patients with TIF-1 antibodies had no evidence of malignancy on extensive cancer screening [65,132,147]. Twenty-two patients (91.6%) had a positive myositis antigen profile (MAP).…”

Section: Idiopathic Inflammatory Myositismentioning

confidence: 99%

New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review

Nune,

Durkowski,

Pillay

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…DM after SARS-CoV-2 infection itself has been sporadically reported. 9 The aetiological relationship between DM and COVID-19 vaccination is still unknown. Vaccination may induce DM by activating the immune system, resulting in immune disturbances and dysregulation.…”

Section: Discussionmentioning

confidence: 99%

“…DM after SARS‐CoV‐2 infection itself has been sporadically reported 9 . The aetiological relationship between DM and COVID‐19 vaccination is still unknown.…”

Section: Discussionmentioning

confidence: 99%

Dermatomyositis following COVID‐19 vaccination: Temporal or causal association?

Lahouel

Salah

Mokni

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

Several cutaneous complications have been reported with COVID‐19 vaccines. Most of them are benign and consist mainly of delayed local reactions, urticaria, and morbilliform eruptions. Dermatomyositis (DM) is a multi‐system autoimmune disorder primarily affecting the skin, skeletal muscle and blood vessels. We describe a rare case of DM after administering the first dose of the Pfizer‐BioNTech COVID‐19 vaccine. The causal relation was suggested based on the timing of the onset and the absence of other triggering factors.

show abstract

“…In our case a diagnosis of paraneoplastic dermatomyositis was made since it was associated with a breast cancer. Although in the literature a few cases of dermatomyositis with TIF-1 gamma antibodies temporally related with SARS-CoV-2 vaccination [27,28] have been reported, retrospective and epidemiological studies failed to ascertain an association between DM and vaccines. In fact, no significant increase in the incidence of DM was reported after large vaccination campaigns [29].…”

Section: Discussionmentioning

confidence: 99%

Lymphedema of the Arm after COVID-19 Vaccination in a Patient with Hidden Breast Cancer and Paraneoplastic Dermatomyositis

et al. 2022

View full text Add to dashboard Cite

The pandemic outbreak of Coronavirus Disease 2019 (COVID-19) led to the development of mRNA vaccines. With the extensive vaccination campaign performed worldwide, many adverse reactions to these drugs have been reported in the literature. Although most of them are mild and self-limiting, they may sometimes cause psychological stress and require efforts to make a differential diagnosis with other conditions. This is the case of lymphadenopathies and lymphedema in patients with a history of cancer. Herein we present a case of lymphedema of the arm developed ten days after a VAXZEVRIA COVID-19 vaccine shot in a patient who had concomitant signs and symptoms compatible with a diagnosis of dermatomyositis. It was later classified as paraneoplastic as instrumental investigation revealed a breast carcinoma contralateral to the site of vaccine injection. With this report we ponder an adverse reaction to COVID-19 vaccination with the aim of bringing new data for clinicians who face similar clinical presentations, particularly controversial for radiologists and oncologists.

show abstract

Onset of amyopathic dermatomyositis following mRNA‐based SARS‐CoV‐2 vaccination

Abstract: The mechanism of onychomadesis (nail shedding) and beau's lines following hand-foot-mouth disease.

Cited by 13 publications

References 10 publications

New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review

New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review

Dermatomyositis following COVID‐19 vaccination: Temporal or causal association?

Lymphedema of the Arm after COVID-19 Vaccination in a Patient with Hidden Breast Cancer and Paraneoplastic Dermatomyositis

Contact Info

Product

Resources

About